首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group. (vol 12, pg 1434, 2017)

【24h】

Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group. (vol 12, pg 1434, 2017)

机译：可切除的临床N2非小细胞肺癌; 什么是最佳的治疗策略？英国胸部社会肺癌专家咨询小组更新。（第12卷，PG 1434,2017）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2019年第2期|共1页
作者
Evison M.; Clive A.; Castle L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group. (vol 12, pg 1434, 2017) [J] . Evison M., Clive A., Castle L. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第2期

机译：可切除的临床N2非小细胞肺癌; 什么是最佳的治疗策略？英国胸部社会肺癌专家咨询小组更新。（第12卷，PG 1434,2017）
2. Corrigendum to “Routine preoperative brain CT in resectable non-small cell lung cancer—Ten years experience from a tertiary UK thoracic center” [Lung Cancer 122 (August) (2018) 195–199] [J] . Tomasz Matys, Rosalyn Drury, Sarojini David, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2018,第期

机译：“常规术前脑CT在第三届英国胸部中心可重新入手的非小细胞肺癌 - 十年经验中的常规术前脑CT”[肺癌122（八月）（2018）195-199]
3. Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: what is the role for surgery? [J] . Awan Musaddiq, Sharma Neelesh, Towe Christopher W., Expert review of anticancer therapy . 2016,第11期

机译：纵隔淋巴结阳性（N2）可切除的非小细胞肺癌的最佳治疗：手术的作用是什么？
4. Dosimetric and Clinical Benefits of Conformal Radiotherapy Plus Volumetric Modulated Arc Therapy in the Treatment of Non-small Cell Lung Cancer [C] . Xiance Jin, Congying Xie World Congress on Medical Physics and Biomedical Engineering . 2015

机译：保形放疗的剂量和临床益处加容积调节弧治疗非小细胞肺癌
5. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of ontario, canada [D] . Thao, Mallory. 2014

机译：加拿大安大略省非小细胞肺癌患者早期肺癌筛查的成本效益及分子亚群的检测和治疗
6. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. [O] . 1995

机译：非小细胞肺癌的化学疗法：一项荟萃分析使用来自52个随机临床试验中各个患者的最新数据。非小细胞肺癌协作组。
7. Prognostic factors for survival in patients with non-resected non-small-cell lung cancer(Clinical staging IIIA N2, performance status 0, 1). A report from the symposium "treatment for clinical staging IIIA N2 non-small-cell lung cancer" at the 28th annual meeting of the Japan Lung Cancer society. [O] . Kiyoyuki Furuse, Nobuyuki Hara, Hiroshi Nishiwaki, 1989

机译：未切除的非小细胞肺癌患者存活的预后因素（临床分期IIIA N2，性能状态0,1）。在日本肺癌社会第28届年会的第28届年会中“临床临床临床临床临床疗效治疗IIIA N2非小细胞肺癌”的报告。

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号